Skip to content
TrialScanner

NCT05200364

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Phase 1TerminatedSTROLead

Registry record

Lead sponsor
Sutro Biopharma, Inc.
Conditions
Ovarian Cancer; Ovarian Carcinoma; Ovary Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Primary completion
Jun 1, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05200364 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05200364: A Study of STRO-002, an... | TrialScanner